This issue of the Journal of Pharmacy Practice is devoted to the broad spectrum of women's health. Each article contributes to your understanding of the significant disease conditions and physiologic changes that women commonly face. Clinically important areas are summarized to present a snapshot of current controversies and advances. Topics covered include a review of Denosumab, fetal safety of a variety of drugs, triple negative breast cancer (TNBC), current guidelines for the use of hormone replacement therapy, and the potential influence of low-dose combination oral contraceptives on bone development in young women.Representing a new class of drugs, Denosumab, a monoclonal antibody, has Food and Drug Administration (FDA) approval for the treatment of osteoporosis in postmenopausal women. Denosumab is vastly different from older agents and may fill a unique niche in pharmacotherapy regimens. Drs Kira B. Harris, Kimberly L. Nealy, Delilah J. Jackson and Phillip L. Thornton of Wingate University School of Pharmacy provide multiple comparisons between Denosumab and Fosamax, the most commonly prescribed bisphosphonate, will allow you to evaluate its contribution.
展开▼
机译：本期《药学实践杂志》专门针对广泛的女性健康问题。每篇文章都有助于您了解女性通常面临的重大疾病状况和生理变化。总结了临床上重要的领域，以概述当前的争议和进展。涵盖的主题包括Denosumab综述，多种药物的胎儿安全性，三阴性乳腺癌（TNBC），激素替代疗法的当前使用指南以及低剂量联合口服避孕药对年轻人骨骼发育的潜在影响代表一种新型药物的单克隆抗体Denosumab已获得美国食品药品监督管理局（FDA）的批准，用于治疗绝经后妇女的骨质疏松症。地诺单抗与老年药物有很大的不同，可能在药物治疗方案中占据独特的位置。 Wingate大学药学院的Kira B. Harris博士，Kimberly L. Nealy，Delilah J. Jackson和Phillip L. Thornton提供了Denosumab和Fosamax（最常用的双膦酸盐）之间的多重比较，可让您评估其贡献。
展开▼
